Aegea Biotechnologies

Aegea Biotechnologies is an innovation-driven core technology company. Aegea Biotechnologies believes that its science can transform several large markets — life sciences, diagnostics, genomics, next-generation sequencing (NGS), and therapeutics. Aegea Biotechnologies is developing molecular assay reagents, research kits, and in vitro diagnostic (IVD) products based on novel, patented, and proprietary nucleic acid chemistries and methods.AEGEA's patented technologies, including its co-owned "Switch-Blocker" technology for highly sensitive rare mutation detection, give AEGEA’s kits the potential to truly disrupt multi-billion-dollar RUO (Research Use Only) and IVD molecular analysis fields. AEGEA’s kits are designed to deliver detection and test results with unprecedented sensitivity and specificity — rapidly and using established assay formats, instruments, and reagents. Additionally, AEGEA provides customized solutions, including assay development and technical adaptation for different platforms, to various types of enterprises, including pharmaceutical and biotechnology companies, diagnostic firms, and DNA sequencing companies.In total, AEGEA owns 11 U.S. issued patents related to nucleic acid technologies as well as foreign equivalents. One of AEGEA’s rare mutation detection patents has been validated and is already clinically used to identify biomarkers in cancer patients.